Arcadia Biosciences (NASDAQ:RKDA) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a note issued to investors on Tuesday. The firm set a “sell” rating on the basic materials company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Arcadia Biosciences in a report on Friday, April 5th.

Arcadia Biosciences Price Performance

Shares of NASDAQ RKDA opened at $2.02 on Tuesday. The company has a 50 day simple moving average of $2.22 and a 200 day simple moving average of $2.67. Arcadia Biosciences has a 1 year low of $1.85 and a 1 year high of $6.50. The firm has a market cap of $2.75 million, a PE ratio of -0.14 and a beta of 0.62.

Arcadia Biosciences (NASDAQ:RKDA) last issued its quarterly earnings results on Thursday, March 28th. The basic materials company reported ($2.48) EPS for the quarter, topping analysts’ consensus estimates of ($2.68) by $0.20. The company had revenue of $1.17 million for the quarter, compared to analyst estimates of $1.80 million. Arcadia Biosciences had a negative net margin of 246.80% and a negative return on equity of 81.56%. As a group, research analysts anticipate that Arcadia Biosciences will post -5.01 earnings per share for the current fiscal year.

About Arcadia Biosciences

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.